PCSA
PCSA clinical trials: Processa Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Processa Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PCSA on the catalyst calendar · PCSA registry changes
- Primary completion Jul 29, 2026ActualPhase 2NCT06568692A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerProcessa Pharmaceuticals · Breast CancerTerminatedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2022ActualPhase 2NCT05270460Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisProcessa Pharmaceuticals · GastroparesisCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2020ActualPhase 2NCT03698864A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis LipoidicaProcessa Pharmaceuticals · Necrobiosis LipoidicaCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2024ActualPhase 1NCT04861987A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract TumorsProcessa Pharmaceuticals · Advanced CancerCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2019ActualPhase 1/Phase 2NCT03189914RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic CancerProcessa Pharmaceuticals · Metastatic Pancreatic CancerCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2019ActualPhase 1/Phase 2NCT02030067Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced MalignanciesProcessa Pharmaceuticals · Solid TumorCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2023ActualPhase 2NCT04800562A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaProcessa Pharmaceuticals · Necrobiosis LipoidicaTerminatedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2016ActualPhase 2NCT01978366Open Label Extension Study of HT-100 in Patients With DMDProcessa Pharmaceuticals · Duchenne Muscular DystrophyTerminatedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2016ActualPhase 1/Phase 2NCT01847573Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyProcessa Pharmaceuticals · Duchenne Muscular DystrophyTerminatedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2018ActualPhase 1NCT03836222Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered...Processa Pharmaceuticals · HealthyCompletedPCSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner